For this year’s annual finance outlook article, appearing in Life Science Leader’s December 2020 issue, we had 10 financial executives take part — 8 being biopharmaceutical company CFOs. As we couldn’t fit all of the wisdom offered into this year’s print edition, we share it here via our Beyond The Printed Page online section of the magazine.
Seventeen top executives of companies representing the entrepreneurial edge of biopharma innovation answer our call for feedback on how the COVID pandemic and the politics surrounding it could affect their futures and the industry.
This year’s CEO outlook article in Life Science Leader’s annual outlook issue, published in December, has 15 CEOs taking part! Some members of this year’s CEO class were posed a question around what COVID-19 induced trends they envisioned sticking around well beyond the end of this pandemic.
Unprecedented. That’s the word used ad nauseam to describe much of what we experienced in 2020. And while many of these moves were unprecedented at the time, now that they’ve been done, they now serve as a precedent. This makes you wonder just how many COVID-19 causations will continue into 2021 and beyond?
Chief Editor Rob Wright talks about the last time he spoke with Henri Termeer, who was a mentor to Paula Ragan, Ph.D., cofounder and CEO of X4 Pharmaceuticals (subject of the November 2020 cover feature in Life Science Leader).
Paula Ragan, Ph.D., cofounder and CEO of X4 Pharmaceuticals (subject of the November 2020 cover feature in Life Science Leader), talks about how participating in team sports can help with leadership skills later in life.
David Lucchino, cofounder and CEO of Frequency Therapeutics, discusses how he came to meet company cofounders Robert Langer, Sc.D., and Chris Loose, Ph.D., along with transitioning from med tech to biopharma.